Safety and feasibility of chemotherapy followed by liver transplantation for patients with definitely unresectable colorectal liver metastases: insights from the TransMet randomised clinical trial.
Fiche publication
Date publication
juin 2024
Journal
EClinicalMedicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr HEYD Bruno
Tous les auteurs :
Adam R, Badrudin D, Chiche L, Bucur P, Scatton O, Granger V, Ducreux M, Cillo U, Cauchy F, Lesurtel M, Mabrut JY, Verslype C, Coubeau L, Hardwigsen J, Boleslawski E, Muscari F, Jeddou H, Pezet D, Heyd B, Lucidi V, Geboes K, Lerut J, Majno P, Grimaldi L, Boukhedouni N, Piedvache C, Gelli M, Levi F, Lewin M
Lien Pubmed
Résumé
Despite the increasing efficacy of chemotherapy (C), the 5-year survival rate for patients with unresectable colorectal liver metastases (CLM) remains around 10%. Liver transplantation (LT) might offer a curative approach for patients with liver-only disease, yet its superior efficacy compared to C alone remains to be demonstrated.
Mots clés
Chemotherapy, Colorectal liver metastases, Liver transplantation, Randomised clinical trial
Référence
EClinicalMedicine. 2024 06;72:102608